AVP Inhibitors

AVP inhibitors encompass a diverse group of chemicals with the primary aim of modulating arginine vasopressin (AVP) activity. Conivaptan and Tolvaptan, as vasopressin V1A and V2 receptor antagonists, respectively, directly inhibit AVP by blocking its receptors. Conivaptan antagonizes both V1A and V2 receptors, interfering with AVP-mediated vasoconstriction and water retention. In contrast, Tolvaptan selectively targets the V2 receptor, disrupting AVP's role in water reabsorption in the renal collecting ducts. These specific receptor antagonists provide focused inhibition of AVP's actions in vascular and renal processes. Lixivaptan and Mozavaptan, also V2 receptor antagonists, further contribute to the inhibition of AVP by disrupting water reabsorption in the kidneys. SR49059 and YM087, as V1A receptor antagonists, specifically interfere with AVP-mediated vasoconstriction, emphasizing their role in modulating AVP activity in processes related to vascular tone regulation. OPC-31260 and SR121463, both V2 receptor antagonists, provide targeted inhibition of AVP's role in water balance regulation in the kidneys.

Relcovaptan and Nelivaptan, acting as V1A and V2 receptor antagonists, respectively, contribute to the inhibition of AVP by targeting vasoconstriction and water reabsorption processes. ABT-627, an endothelin receptor antagonist, indirectly influences AVP by blocking endothelin receptors, impacting AVP release and vascular tone regulation. L-371257, a V2 receptor antagonist, provides specific inhibition of AVP-mediated water reabsorption in the renal collecting ducts. The targeted inhibition provided by these chemicals allows for a nuanced understanding of AVP's